• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

他克莫司毒性伴轻微临床表现:一例病例报告及文献综述

Tacrolimus Toxicity With Minimal Clinical Manifestations: A Case Report and Literature Review.

作者信息

Haroon Nivin, Singh Atul, Bhat Zeenat Yousuf

机构信息

Division of Nephrology, Department of Internal Medicine, Wayne State University, Detroit, MI.

出版信息

Am J Ther. 2016 Mar-Apr;23(2):e631-4. doi: 10.1097/MJT.0000000000000219.

DOI:10.1097/MJT.0000000000000219
PMID:25730156
Abstract

Tacrolimus (FK 506 or Fujimycin) is an effective anti-T-cell agent derived from the fungus Streptomyces tsukubaensis. Some in vitro studies have demonstrated that the potency of tacrolimus can be up to 100 times to that of cyclosporine. Despite being a very potent immunosuppressant, its use is complicated by narrow therapeutic range, individual variation in pharmacokinetics, and a broad spectrum of drug interactions. We report a case of very high tacrolimus level (>120 ng/mL) in a patient who was on antiretroviral medication and tacrolimus. Despite having such high drug levels, patient's clinical presentation and course was benign. He was managed conservatively and this ordeal resulting in no long-term sequela.

摘要

他克莫司(FK 506或普乐可复)是一种从筑波链霉菌中提取的有效的抗T细胞药物。一些体外研究表明,他克莫司的效力可比环孢素高100倍。尽管它是一种非常强效的免疫抑制剂,但其使用因治疗窗窄、药代动力学个体差异以及广泛的药物相互作用而变得复杂。我们报告了一例正在接受抗逆转录病毒药物治疗并服用他克莫司的患者,其他克莫司水平非常高(>120 ng/mL)。尽管药物水平如此之高,但患者的临床表现和病程却是良性的。他接受了保守治疗,这场磨难并未导致长期后遗症。

相似文献

1
Tacrolimus Toxicity With Minimal Clinical Manifestations: A Case Report and Literature Review.他克莫司毒性伴轻微临床表现:一例病例报告及文献综述
Am J Ther. 2016 Mar-Apr;23(2):e631-4. doi: 10.1097/MJT.0000000000000219.
2
Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report.姜黄摄入继发急性钙调神经磷酸酶抑制剂肾毒性:一例报告
Transplant Proc. 2017 Jan-Feb;49(1):198-200. doi: 10.1016/j.transproceed.2016.11.029.
3
Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.CYP3A5基因多态性及其对他克莫司血药浓度的影响。
Exp Clin Transplant. 2015 Apr;13 Suppl 1:197-200.
4
The safety of calcineurin inhibitors for kidney-transplant patients.钙调神经磷酸酶抑制剂对肾移植患者的安全性。
Expert Opin Drug Saf. 2015 Oct;14(10):1531-46. doi: 10.1517/14740338.2015.1083974. Epub 2015 Sep 2.
5
Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.肾移植后钙调神经磷酸酶抑制剂对对氧磷酶和芳基酯酶活性的影响。
Exp Clin Transplant. 2014 Aug;12(4):334-42. doi: 10.6002/ect.2013.0110. Epub 2014 Jan 20.
6
Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.在接受钙调神经磷酸酶抑制剂治疗的肾移植受者中,采用淋巴细胞三磷酸腺苷检测进行免疫监测。
Exp Clin Transplant. 2014 Jun;12(3):195-9.
7
Conversion from tacrolimus to cyclosporine for a non-dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report.因他克莫司非剂量依赖性毒性反应转换为环孢素治疗,1例小儿肾移植受者病例报告
Transplant Proc. 2004 Jun;36(5):1332-5. doi: 10.1016/j.transproceed.2004.05.039.
8
Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.肾移植中他克莫司与环孢素A微乳剂相比的疗效和安全性:2年随访结果
Nephrol Dial Transplant. 2005 May;20(5):968-73. doi: 10.1093/ndt/gfh739. Epub 2005 Mar 1.
9
Visual loss associated with tacrolimus: case report and review of the literature.与他克莫司相关的视力丧失:病例报告及文献综述
Cutan Ocul Toxicol. 2010 Jun;29(2):137-9. doi: 10.3109/15569521003662963.
10
Progressive neurological disease induced by tacrolimus in a renal transplant recipient: case presentation.他克莫司诱发肾移植受者发生进行性神经疾病:病例报告
BMC Nephrol. 2006 Mar 31;7:7. doi: 10.1186/1471-2369-7-7.

引用本文的文献

1
Management of Atopic Dermatitis: The Role of Tacrolimus.特应性皮炎的管理:他克莫司的作用。
Cureus. 2022 Aug 18;14(8):e28130. doi: 10.7759/cureus.28130. eCollection 2022 Aug.